Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03909074
Other study ID # PRO-EV71-3003
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 10, 2019
Est. completion date November 13, 2019

Study information

Verified date January 2020
Source Sinovac Biotech Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the non-inferiority of experimental EV71 vaccine compared to the control EV71 vaccine in children aged 36-71 months, to evaluate the non-inferiority of EV71 vaccine used in children aged 36-71 months compared to 6-35 months. The experimental vaccine was manufactured by Sinovac Biotech Co., Ltd, and the control vaccine was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.


Description:

This study is a randomized, double-blind, single-center, controlled phase III clinical trial in children aged 36-71 months, and bridging trial between agegroup of 6-35 and 36-71 months. The purpose of this study is to evaluate the immunogenicity and safety of the experimental EV71 vaccine in children aged 36-71 months. The primary objective of this study is to evaluate the non-inferiority of experimental EV71 vaccine compared to the control EV71 vaccine in children aged 36-71 months, and the non-inferiority of EV71 vaccine used in children aged 36-71 months compared to 6-35 months. The secondary objective is to evaluate the safety of the experimental vaccine used in children aged 36-71 months. The experimental vaccine is manufactured by Sinovac Biotech Co., Ltd, and the control vaccine is manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences. 600 children aged 36-71 months will be randomly assigned in to receive the experimental vaccine or control vaccine, and 300 children aged 6-35 months will receive the experimental vaccine.


Recruitment information / eligibility

Status Completed
Enrollment 900
Est. completion date November 13, 2019
Est. primary completion date June 17, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 71 Months
Eligibility Inclusion Criteria: - Healthy volunteers = 2 years old; - Proven legal identity; - Participants or guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment. Exclusion Criteria: - Prior vaccination with EV71 vaccine; - History of hand, foot and mouth disease; - History of allergy to any vaccine or vaccine ingredient, asthma, serious adverse reactions to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc; - Congenital malformation, developmental disorders, genetic defects, or severe malnutrition; - Autoimmune disease or immunodeficiency/immunosuppressive; - Severe/uncontrollable nervous system disease (epilepsy, seizures or convulsions) or mental illness; - History of thyroidectomy, no spleen and functional spleen; - Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders; - Receipt of any of the following products: 1. Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry 2. Blood products within 2 months prior to study entry 3. Any other investigational products (drug or vaccine)within 30 days prior to study entry 4. Any live attenuated vaccine within 14 days prior to study entry 5. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry; - Acute disease or acute stage of chronic disease within 7 days prior to study entry; - Axillary temperature > 37.0 °C; - Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
36-71 months old children-experimental EV71 vaccine.
Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
36-71 months old children-control EV71 vaccine.
Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.
6-35 months old children-experimental EV71 vaccine.
Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.

Locations

Country Name City State
China Yun County Center for Disease Control and Prevention Lincang Yunnan

Sponsors (1)

Lead Sponsor Collaborator
Sinovac Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The seroconversion rates (SCR) of the EV71 neutralizing antibody calculated based on the cutoff value of 1:8 Subjects whose pre-immune antibody titer < 1:8 and post-immune antibody titer = 1:8, or those whose pre-immune antibody titer = 1:8 and the increase of post-immune antibody level = 4 folds are considered seroconverted. 30 days after two doses
Primary The Geometric mean titer (GMT) of the EV71 neutralizing antibody in the susceptible population The susceptible population refer to the subjects whose pre-immune antibody titer <1:8 30 days after two doses
Secondary The overall incidence of adverse reactions After each dose, a 30-minute safety observation will be conducted immediately. The body temperature, solicited local and general adverse events (AE) on day 0-7 were reported. The solicited local symptoms include pain, induration, redness, swelling, rash, and pruritus. The solicited general adverse symptoms include allergy, fatigue, irritability, inappetence, vomiting, diarrhea, and fever. Unsolicited adverse events on day 0-30 were also reported, which include the unsolicited symptoms happened within 0-7 days, and any symptoms happened within the 8-28 days. Each AE case will be reviewed by the investigator to determine whether it was an adverse reaction (The vaccination-related AE). The incidence of adverse reactions=Number of subjects who have adverse reactions of any symptoms/number of all the subjects whose safety information are collected. 0-30 days after each dose
Secondary The incidence of the serious adverse events (SAE) After each dose, the serious adverse events in the safety observation period will be reported. The SAE incidence=Number of subjects who have SAE of any symptoms/Number of subjects whose safety information are collected. 0-30 days after each dose
Secondary The seroconversion rates (SCR) of the EV71 neutralizing antibody calculated based on the cutoff value of 1:16, 1:32, and 1:64 respectively Subjects whose pre-immune antibody titer <1:16(1:32/1:64) and post-immune antibody titer =1:16(1:32/1:64), or those whose pre-immune antibody titer = 1:16(1:32/1:64) and the increase of post-immune antibody level = 4 folds are considered seroconverted. 30 days after two doses
Secondary The Geometric mean titer (GMT) of the EV71 neutralizing antibody The GMT 30 days after two doses. 30 days after two doses
See also
  Status Clinical Trial Phase
Recruiting NCT06063057 - Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial Phase 1/Phase 2
Completed NCT04133584 - The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine Phase 4
Completed NCT03241030 - Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Phase 2
Completed NCT01255124 - Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children N/A
Completed NCT03873740 - Immunogenicity and Safety of Two Different Commercial EV71 Vaccines Phase 4
Completed NCT05637229 - A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia
Recruiting NCT06146088 - Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine Phase 4
Active, not recruiting NCT06209398 - Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine Phase 4
Recruiting NCT01175915 - A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Recruiting NCT01145664 - A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease N/A
Completed NCT01182532 - A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Completed NCT03281174 - Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine N/A
Completed NCT03582761 - Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71 Phase 4
Completed NCT03903926 - Efficacy Trial of a Commercial EV71 Vaccine Phase 4
Completed NCT02001233 - A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine
Completed NCT01769794 - Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study N/A
Recruiting NCT01182025 - A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Recruiting NCT06263439 - Surveillance of HFMD in Pediatric Outpatients
Not yet recruiting NCT05397587 - An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell) Phase 4
Completed NCT04111432 - Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines Phase 4